Oncologic imaging end-points for the assessment of therapy response

Recent Patents on Anti-Cancer Drug Discovery

Volumn 4, Issue 1, 2009, Pages 36-53

  Serkova, Natalie J ^a,b   Garg, Kavita ^a   Bradshaw Pierce, Erica L ^a,b  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

Computed tomography; Contrast agent; Magnetic resonance imaging; Molecular imaging; Molecular probes; Nanoparticles; Optical imaging; Positron emission tomography; Radioisotopes

Indexed keywords

ANTINEOPLASTIC AGENT; BASIC FIBROBLAST GROWTH FACTOR; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; GLUCOSE TRANSPORTER 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMATINIB; METHOTREXATE; PLATELET DERIVED GROWTH FACTOR; TRANSFORMING GROWTH FACTOR ALPHA; VASCULAR TARGETING AGENT; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ALOPECIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER DIAGNOSIS; CANCER RESEARCH; CANCER STAGING; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DIARRHEA; DIFFUSION WEIGHTED IMAGING; DISTANT METASTASIS; DRUG EFFICACY; ECHOGRAPHY; GASTROINTESTINAL STROMAL TUMOR; GENITAL SYSTEM DISEASE; HUMAN; LIVER CELL CARCINOMA; LYMPH NODE METASTASIS; MAGNETIC FIELD; MALIGNANT NEOPLASTIC DISEASE; MAXIMUM TOLERATED DOSE; MOLECULAR IMAGING; MUCOSA INFLAMMATION; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OPTICAL TOMOGRAPHY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR GROWTH; TUMOR VASCULARIZATION; TUMOR VOLUME; WHOLE BODY TOMOGRAPHY; X RAY; ANIMAL; METABOLISM; METHODOLOGY; NEOPLASM; REVIEW; VASCULARIZATION;

ANIMALS; DIAGNOSTIC IMAGING; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 62749157617     PISSN: 15748928     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489209787002434     Document Type: Article

References (200)

1. Vaughan CL, Mayosi BM. Origins of computed tomography. Lancet 2007; 369: 1168.
2. Montgomery BJ. CT scanning recognized with Nobel Prize. JAMA 1979; 342: 2380.
3. Gore J. Out of the shadows - MRI and the Nobel Prize. N Engl J Med 2003; 349: 2290-2292.
4. Lauterbur PC. Nobel Lecture: All science is interdisciplinary - from magnetic moments to molecules to men. Biosci Rep 2004: 24: 165-178.
5. Mansfield P. Snapshot magnetic resonance imging (Nobel lecture). Angew Chem Int Ed Engl 2004; 43: 5456-5464.
6. Bragg DG, Rubin P, Hricak H. "Imaging strategies for oncologic diagnosis and multidisciplinary treatment" in "Oncologic Imaging" Second Edition by Bragg, Rubin and Hricak, W.B. Saunders Company, Philidelphia 2002; 3-8.
7. Weissleder R, Mahmood U. Molecular imaging. Radiology 2001; 219: 316-333.
8. Tidwell AS, Jones JC. Advanced imaging concepts: A pictorial glossary of CT and MRI technology. Clin Tech Small Anim Pract 1999; 14: 65-111.
9. Hylton N. Dynamic contrast-enhanced magnetic resonance imaging as an imaging biomarker. J Clin Oncol 2006; 24: 3293-3298.
10. Choyke PL, Kobayashi H. Functional magnetic resonance imaging of the kidney using macromolecular contrast agents. Abdom Imaging 2006; 31: 224-231.
11. Leach MO. Magnetic resonance spectroscopy (MRS) in the investigation of cancer at The Royal Marsden Hospital and The Institute of Cancer Research. Phys Med Biol 2006; 51: 61-82.
12. Gillies RJ, Morse DL. in vivo Magnetic resonance spectroscopy in cancer. Annu Rev Biomed Eng 2005; 7: 287-326.
13. Driehuys, B.: US20080089846 (2008).
14. Whitham, C.: US20070286331 (2007).
15. Rousso, B., Ben-Haim, S., Nagler, M., Ziv, O., Ravhon, R., Dickman, D., Zilberstein, Y., Dichterman, E., Ben-haim, S., Vallabhajosula, S., Berman, D., Bronshtine, Z., Popper, Z., Weissberg, N., Roth, N., Melman, H.: US20080128626 (2008).
16. 18FFDG PET/CT in the treatment of head and neck cancers: Principles, technique, normal distribution, and initial staging. Am J Roentgenol 2005; 184: 579-587.
17. Gambhir SS. Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer 2002; 2: 683-693.
18. Raffel, D. M., Jung, Y.-W., Gildersleeve, D. L.: US20060127309 (2006).
19. Blodgett TM, Meltzer CC, Townsend DW. PET/CT: Form and function. Radiology 2007; 242: 360-385.
20. Townsend, D. W., Nutt, R.: US20040030246 (2004).
21. Wollenweber, S. D., Ganin, A.: US20040260176 (2004).
22. Bolondi L, Correas JM, Lencioni R, Weskott HP, Piscaglia F. New perspectives for the use of contrast-enhanced liver ultrasound in clinical practice. Dig Liver Dis 2007; 39: 187-195.
23. Blomley MJK, Eckersley RJ. Functional ultrasound methods in oncological imaging. Eur J Cancer 2002; 2108-2115.
24. Lal, R. M., Sironey, S. A., Patz, T. A.: US20080144897 (2008).
25. Lauenstein TC. "Whole-body magnetic resonance imaging in patients with metastases" in "Cancer Imaging, Volume 2" First Edition by Hyatt, Elsevier Academic Press, Amsterdam, 2008, pp. 155-160.
26. Schmidt GP, Kramer H, Reiser MF, Glaser C. Whole-body magnetic resonance imaging and positron emission tomography-computed tomography in oncology. Top Magn Reson Imag 2007; 18: 193-202.
27. Coche E. Screening for lung cancer with low-dose CT. JBR-BTR 2008; 91: 1-5.
28. Schrevens L, Lorent N, Dooms C, Vansteenkiste J. The role of PET scan in diagnosis, staging, and management of non-small cell lung cancer. Oncologist 2004; 9: 633-643.
29. Garbow JR, Zhang Z, You M. Detection of primary lung tumors in rodents by magnetic resonance imaging. Cancer Res 2004; 64: 2740-2742.
30. Riedl CC, Ponhold L, Flory D, et al. Magnetic resonance imaging of the breast improves detection of invasive cancer, preinvasive cancer, and premalignant lesions during surveillance of women at high risk for breast cancer. Clin Cancer Res 2007; 13: 6144-6152.
31. Jacobs MA, Barker PB, Argani P, et al. Combined dynamic-contrast enhanced breast MR and proton spectroscopic imaging: A feasibility study. J Magn Reson Imaging 2005; 21: 23-28.
32. Bittner, C.: US20040254444 (2004).
33. Kim CK, Park BK. Update of prostate magnetic resonance imaging at 3T. J Comput Assist Tomogr 2008; 32: 163-172.
34. Pucar D, Sella T, Schroder H. The role of imaging in the detection of prostate cancer local recurrence after radiation therapy and surgery. Curr Opin Urol 2008; 18: 87-97.
35. Prando A, Kurhanewicz J, Borges AP, Oliveira EM, Figueiredo F. Prostatic biopsy directed with endorectal MR spectroscopic imaging findings with elevated prostate specific antigen levels and prior negative biopsy findings: early experience. Radiology 2005; 236: 903-910.
36. Daum, W.: US20040092810 (2004).
37. Degrassi A, Russo M, Scanziani E, et al. Magnetic resonance imaging and histopathological characterization of prostate tumors in TRAMP mice as model for pre-clinical trials. Prostate 2007; 67: 396-404.
38. Shah GV, Wesolowski JR, Ansari SA, Mukherji SK. New directions in head and neck imaging. J Surg Oncol 2008; 97: 644-648.
39. Mikulis DJ, Roberts TP. Neuro MR: Protocols J Magn Reson Imaging 2007; 26: 838-847.
40. Cha S. Perfusion MR imaging of brain tumors. Top Magn Reson Imaging 2004; 15: 279-289.
41. Tsika AA. Proton magnetic resonance spectroscopic imaging as a cancer biomarker for pediatric brain tumors. Int J Oncol 2008; 32: 517-526.
42. Debatin JF, Lauenstein TC. Virtual magnetic resonance colonography. Gut 2003; 52: 17-22.
43. Silva AC, Vens EA, Hara AK, et al. Evaluation of benign and malignant rectal lesions with CT colonography and endoscopic correlation. Radiographics 2006; 26: 1085-1099.
44. Weichert, J.: US20070098633 (2007).
45. Kim SH, Choi BI, Lee JY, et al. Diagnostic accuracy of multi-/ single-detector row CT and contrast-enhanced MRI in the detection of hepatocellular carcinomas meeting the Milan criteria before liver transplantation. Intervirology 2008; 51: 52-60.
46. Kim YK, Kwak HS, Kim CS, et al. Hepatocellular carcinoma in patients with chronic liver disease: Comparison of SPIO-enhanced MR imaging and 16-detecyor row CT. Radiology 2006; 238: 531-541.
47. Follen M, Levenback CF, Iver RB, et al. Imaging in cervical cancer. Cancer 2003; 98: 2028-2038.
48. Blake MA, Kalra MK. Imaging of urinary tract tumors. Cancer Treat Res 2008; 143: 299-317.
49. Denzinger S, Wieland WF, Otto W, et al. Does photodynamic transurethral resection of bladder tumors improve the outcome of initial T1 high-grade bladder cancer? BJU Int 2008; 101: 566-569.
50. Folkman J. Tumor angiogenesis: Therapeutic implication. N Engl J Med 1971; 285: 1182-1186.
51. Ferrara N. Vascular endothelial growth factor. Eur J Cancer 1996; 32: 2413-2422.
52. Folkman J. What is the evidence that tumors are angiogensis dependent ? J Nat Cancer Inst 1990; 82: 4-6.
53. Jain RK. Molecular regulation of vessel maturation. Nat Med 2003; 9: 685-693.
54. Ferrara N. Vascular endothelial growth factor as a target for anticancer therapy. Oncologist 2004; 9: 2-10.
55. Dancey J, Sausville EA. Issues and progress with protein kinase inhibitors for cancer treatment. Nat Rev Drug Disc 2003; 2: 296-313.
56. Hashizume H, Baluk P, Morikawa S, et al. Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol 2000; 156: 1363-1380.
57. Rankin EB, Giaccia AJ. The role of hypoxia-inducible factors in tumorigenesis. Cell Death Differ 2008;15: 678-685.
58. Weinmann M, Belka C, Plasswilm L. Tumour hypoxia: Impact on biology, prognosis and treatment of solid malignant tumours. Onkologie 2004; 27: 83-90.
59. 2 homeostasis. Curr Opin Genet Dev 1998; 8: 588-594.
60. Barrett T, Brechbiel M, Bernardo M, Choyke PL. MRI of tumor angiogenesis. J Magn Reson Imag 2007; 26: 235-249.
61. Thomassin-Naggara I, Bazot M, Darai E, et al. Epithelial ovarian tumors: Values of dynamic contrast-enhanced MR imaging and correlation with tumor angiogenesis. Radiology 2008; 248: 148-159.
62. Zahara MA, Hollingsworth KG, Sala E, Lomas DJ, Tan LT. Dynamic contrast-enhanced MRI as a predictor of tumor response to radiotherapy. Lancet Oncol 2007; 8: 63-74.
63. Moasser MM, Wilmes LJ, Wong CH, et al. Improved vascular function following high-dose epidermal growth factor receptor tyrosine kinase inhibitor therapy. J Magn Reson Imag 2007; 26: 1618-1625.
64. Robinson SP, McIntyre DJO, Checkley D, et al. Tumor dose response to the antivascular agent ZD6126 assessed by magnetic resonance imaging. Br J Cancer 2003; 88: 1592-1597.
65. Marzola P, Degrassi A, Calderan L, et al. in vivo Assessment of antiangiogenic activity of SU6668 in an experimental colon carcinoma model. Clin Cancer Res 2004; 10: 739-750.
66. Marzola P, Degrassi A, Calderan L, et al. Early antiangiogenic activity of SU11248 evaluated in vivo by dynamic contrast-enhanced magnetic resonance imaging in an experimental model of colon carcinoma. Clin Cancer Res 2005; 11: 5827-5832.
67. Tofts PS, Brix G, Buckley DL, et al. Estimating kinetic parameters from dynamic contrast-enhanced T1-weighted MRI of a diffusable tracer: Standardized quantities and symbols. J Magn Reson Imag 1999; 10: 223-232.
68. Roberts C, Issa B, Stone A, et al. Comparative study into the robustness of compartmental modeling and model-free analysis in DCE-MRI studies. J Magn Reson Imag 2006; 23: 554-563.
69. O'Conner J, Jackson A, Parker G, Jayson G. DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents. Br J Cancer 2007; 96: 189-195.
70. Wilmes LJ, Pallavicini MG, Fleming LM, et al. AF-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by contrast-enhanced magnetic resonance imaging. Magn Reson Imaging 2007; 25: 319-327.
71. Checkley D, Tessier JJ, Kendrew J, Waterton JC, Wedge SR. Use of dynamic contrast-enhanced MRI to evaluate acute treatment with ZD6474, a VEGF signaling inhibitor, in PC-3 prostate tumors. Br J Cancer 2003; 89: 1889-1895.
72. Troiani T, Serkova NJ, Gustafson DL, et al. Investigation of two dosing schedules of Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signaling, in combination with Irinotecan in a human colon cancer xenograft model. Clin Cancer Res 2007; 13: 6450-6458.
73. Hahn OM, Yang C, Medved M, et al. Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. J Clin Oncol 2008; 28: 4572-4578.
74. Jesberger, J., Duerk, J. L., Lewin, J. S.: US20040044281 (2004).
75. Miles KA, Young H, Chica SL, Esser PD. Quantitative contrast-enhanced computed tomography: Is there a need for system calibration? Eur Radiol 2007; 17: 919-926.
76. Bisdas S, Medov L, Baghi M, et al. A comparison of tumor perfusion assessed by deconvolution-based analysis of dynamic contrast-enhanced CT and MR imaging in patients with squamous cell carcinoma of the upper aerodigetsive tract. Eur Radiol 2008; 18: 843-850.
77. Padhani AR, Krohn KA, Lewis JS, Alber M. Imaging of oxygenation of human tumours. Eur Radiol 2007; 17: 861-872.
78. Kennan RP, Scanley BE, Gore JC. Physiologic basis for BOLD MR signal changes due to hypoxia/hyperoxia: Separation of blood volume and magnetic susceptibility effects. Magn Reson Med 1997; 37: 953-956.
79. Salomon, Y., Neeman, M., Scherz, A., Gross, S., Gilad, A.: US20060135868 (2006).
80. Rajopadhye, M., Edwards, D.S., Barrett, J.A., Carpenter, J. A. P., Harris, T. D., Heminway, S. D., Liu, S., Prahlad, S. R.: US20060003926 (2006).
81. Koh DM, Collins DJ. Diffusion-weighted MRI in the body: Application and challenges in oncology. Am J Roentgenol 2007; 188: 622-635.
82. Desouza NM, Reinsberg SA, Scurr ED, Brewster JM, Payne GS. Magnetic resonance imaging in prostate cancer: The value of apparent diffusion coefficient for identifying malignant nodules. Br J Radiol 2007; 80: 90-95.
83. Reinsberg SA, Payne GS, Riches SF, et al. Combined use of diffusion-weighted MRI and 1H-MR spectroscopy to increase accuracy in prostate cancer detection. Am J Roentgenol 2007; 188: 91-88.
84. Warburg O. "The Metabolism of Tumors", London: Constable Press, 1930.
85. Summerton, J. E.: US20080124274 (2008).
86. Gambhir SS, Czernin J, Schwimmer J, et al. A tabulated summary of the FDG-PET literature. J Nucl Med 2001; 42: 1-93.
87. Collins CD. PET/CT in oncology: For which tumors is it the reference standard? Cancer Imag 2007; 7: 77-S87.
88. Kato F, Tsukamoto E, Suginami Y, et al. Visualization of normal organs in whole-body FDG-PET imaging. Kaku Igaku 1999; 36: 971-977.
89. Kostakoglu L, Agress H, Goldsmith SJ. Clinical role of FDG-PET in evaluation of cancer patients. Radiographics 2003: 23: 315-340.
90. Vesselle H, Freeman JD, Wiens L, et al. Fluorodeoxyglucose uptake of primary non-small cell lung cancer at positron emission tomography: New contrary data on prognostic role. Clin Cancer Res 2007; 13: 3255-3263.
91. Burrell SC, Van den Abbeele AD. 2-Deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography of the head and neck: An atlas of normal uptake and variants. Mol Imaging Biol 2005; 7: 244-256.
92. Crawford EJ, Christman D, Atkins H, Friedkin M, Wolf AP. Scintigraphy with positron-emitting compounds - I. Carbon-11 labeled thymidine and thymidylate. Int J Nucl Med Biol 1978; 5: 61-69.
93. Vander Borgt T, Pauwels S, Lambotte L, et al. Brain tumor imaging with PET and 2-[carbon-11]thymidine. J Nucl Med 1994; 35: 974-982.
94. Goodman, M. M.: US20070082879 (2007).
95. Nelson SJ. Magnetic resonance spectroscopic imaging. IEEE Eng Med Biol Mag 2004; 23: 30-39.
96. Nelson SJ, Graves E, Pirzkall A, et al. in vivo Molecular imaging for planning radiation therapy of gliomas: An application of 1H MRSI. J Magn Reson Imag 2002; 16: 464-476.
97. Kurhanewicz J, Swanson MG, Nelson SJ, Vigneron DB. Combined magnetic resonance imaging and spectroscopic imaging approach to molecular imaging of prostate cancer. J Magn Reson Imaging 2002; 16: 451-463.
98. Glunde K, Serkova NJ. Therapeutic targets and biomarkers identified in cancer choline phospholipid metabolism. Pharmacogenomics 2006; 7: 1109-1123.
99. Kurhanewicz J, Vigneron DB, Nelson SJ, et al. Citrate as in vivo marker to discriminate prostate cancer from benign prostatic hyperplasia and normal prostate peripheral zone: Detection via localized proton spectroscopy. Urology 1995; 45: 459-466.
100. Celda B, Monleon D, Martinez-Bisbal MC, et al. MRS as an endogenous molecular imaging for brain and prostate tumors: FP6 project "eTUMOR". Adv Exp Med Biol 2006; 587: 285-302.
101. Kurhanewicz J, Bok R, Nelson SJ, Vigneron DB. Current and potential applications of clinical 13C-NMR spectroscopy. J Nuck Med 2008; 49: 341-344.
102. Tesiram, Y. A., Towner, R. A.: US20080081375 (2008).
103. Dromain C, de Baere T, Lumbroso J, et al. Detection of liver metastases from endocrine tumors: A prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging. J Clin Oncol 2005; 23: 70-78.
104. Seute T, Leffers P, Ten Velde G PM, Twijnstra A. Detection of brain metastases from small cell lung cancer. Cancer 2008; 112:1827-1834.
105. Parikh T, Drew SJ, Lee VS, et al. Focal liver lesion detection and characterization with diffusion-weighted MR imaging. Radiology 2008; 246: 812-822.
106. Thomson V, Pialat JB, Gay F, et al. Whole-body MRI for metastases screening: A preliminary study using 3D VIBE sequences with automatic subtraction between noncontrast and contrast enhnaced images. Am J Clin Oncol 2008; 31: 285-292.
107. Lauenstein TC, Goehde SC, Herborn CU, et al. Whole-body MR imaging: Evaluation of patients for metastases. Radiology 2004; 233: 139-148.
108. Suzuki K, Yamamoto M, Hasegamwa Y, et al. Magnetic resonance imaging and computed tomography in the diagnoses of brain metastases of lung cancer. Lung Cancer 2004; 46: 357-360.
109. 18F-FDG PET in evaluating patients with potentially operable non-small cell lung cancer. J Nucl Med 2006; 47: 1607-1611.
110. Park W, Park YJ, Huh, SJ, et al. The usefulness of MRI and PET imaging for the detection of parametial involvement and lymph node metastasis in patients with cervical cancer. Jpn J Clin Oncol 2005; 35: 260-264.
111. Kvistad KA, Rydland J, Smethurst HB, et al. Axillary lymph node metastases in breast cancer: Preoperative detection with dynamic contrast-enhanced MRI. Eur Radiol 2000; 10: 1464-1471.
112. Hövels AM, Heesakkers RAM, Adang EM, et al. The diagnostic accuracy of CT anf MRI in the staging of pelvic lymph nodes in patients with prostate cancer: A meta analysis. Clin Radiol 2008; 63: 387-395.
113. Mattrey, R. F.: US20020197209 (2002).
114. Harisinghani MG, Barentsz J, Hahn PF, et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 2003; 348: 2491-2499.
115. 18F-FDG PET/CT in colorectal liver metastases - comparison with CT and liver MRI. Eur J Nucl Med Mol Imag 2008; 35: 1323-1329.
116. Selzner M, Hany TF, Wildbrett P, et al. Does the novel PET/CT imaging modality impact on the treatment of patients with metastaic colorectal cancer of the liver? Ann Surg 2004; 24: 1027-1036.
117. Sun L, Wu H, Guan, YS. Positron emission tomography/computed tomography: Challenge to conventional imaging modalities in evaluating primary and metastatic liver malignancies. World J Gastroenterol 2007; 13: 2775-2783.
118. Coleman RE. PET in lung cancer. J Nucl Med 1999; 40: 814-820.
119. 11C-methionine play a role in lung cancer staging? J Nucl Med 2000; 41: 291-292.
120. Braams JW, Prumin J, Kole AC, et al. Detection of unknown primary head and neck tumors by positron emission tomography. Int J Oral Maxillofac Surg 1997; 26: 112-115.
121. Jover R, Lauriso D, Gonzalez C, Rojo A, Gorospe L, Alfonso JM. Role of PET/CT in the evaluation of cervical cancer. Gynecol Oncol 2008; doi:10.1016/j.ygyno.2008.05.023.
122. Kinkel K, Lu Y, Both M, Warren RS, Thoeni RF. Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): A meta-analysis. Radiology 2002; 224: 748-756.
123. Delbeke D. Oncological applications of FDG PET imaging: Brain tumors, colorectal cancer, lymphoma and melanoma. J Nucl Med 1999; 40: 591-603.
124. Massoud TF, Gambhir SS. Molecular imaging in living subjects: Seeing fundamental biological processes in a new light. Genes Develop 2003; 17: 545-580.
125. Aime, S., Gianolio, E., Morelli, G., Pedone, C., Tesauro, D., Lattuada, L., Visigalli, M., Anelli, P. L.: US2005008573 (2005).
126. Randey, R. K., Grossman, Z., Kanter, P., Dougherty, T. J.: US20040022737 (2004).
127. Bakam D., Meade, T. J.: US20030021750 (2003).
128. Li, C., Wen, X., Jackson, E. F., Wallace, S.: US20050152842 (2005).
129. Liu, P. K., Kim, Y. R., Rosen, B. R., Liu, C. H.: US20080118440 (2008).
130. Port, M., Corot, C., Raynal, I., Rousseaux, O.: US20040253181 (2004).
131. Ward J, Guthrie JA, Wilson D, et al. Colorectal hepatic metastases: Detection with SPIO-enhanced breath-hold MR imaging - comparison of optimized sequences. Radiology 2003; 228: 709-718.
132. Enoch WS, Harsh G, Hochberg F, Weissleder R. Improved delineation of human brain tumors on MR images using a long-circulating, superparamagnetic iron oxide agent. J Magn Reson Imag 1999: 9: 228-232.
133. Hogemann D, Josephson L, Weissleder R, Basilion JP. Improvement of MRI probes to allow efficient detection if gene expression. Bioconj Chem 2000; 11: 941-946.
134. Anthony AC. Folate receptors. Annu Rev Nutr 1996: 16: 501-521.
135. Artemov D, Mori N, Okollie B, Bhujwalla ZM. MR molecular imaging of the her-2/neu receptor in breast cancer cells using targeted iron oxide nanoparticles. Magn Reson Med 2003; 49: 403-408.
136. Granot D, Addadi Y, Kalchenko V, et al. in vivo Imaging of the systemic recruitment of fibroblasts to the angiogenic rim of ovarian carcinoma tumors. Cancer Res 2007; 67: 9180-9189.
137. 64Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors. J Nucl Med 2001; 42: 213-221.
138. 68Ga]DOTA-D-Phe-1-Tyr3-octreotide: First results in patients with meningiomas. J Nucl Med 2001; 42: 1053-1056.
139. 18F]Galacto-RGD positron emission tomography for imaging of αvβ3 expression on the neurovasculature in patients with squamous cell carcinoma of the head and neck. Clin Cancer Res 2007: 13: 6610-6616.
140. Blasberg R. PET imaging of gene expression. Eur J Cancer 2002; 38: 2137-2146.
141. Shim, H., Jeong, J. M.: US20070258893 (2007).
142. Mach, R. H., Tu, Z.: US20080107599 (2008).
143. Mascal, M.: US20070232521 (2007).
144. Chang SK, Rizvi I, Solban N, Hasan T. in vivo Optical molecular imaging of vascular endothelial growth factor for monitoring cancer treatment. Clin Cancer Res 2008; 14: 4146-4153.
145. Browder T, Butterfield CE, Kraling BM, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000; 60: 1878-1886.
146. Hryniuk W, Levine MN. Dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J Clin Oncol 1986; 4: 1162-1170.
147. Levin L, Hryniuk WM. Dose intensity analysis of chemotherapy regimens in ovarian carcinoma. J Clin Oncol 1987; 5: 756-767.
148. Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991; 325: 164-170.
149. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004; 4: 423-436.
150. Heldin, C. Protein tyrosine kinase receptors. Cancer Surv 1996; 27: 7-24.
151. Levitzki A, Gazit A. Tyrosine kinase inhibition: An approach to drug development. Science 1995; 267: 782-788.
152. Ciardiello F, Tortora G. A novel approach in the treatment of cancer: Targeting the epidermal growth factor receptor. Clin Cancer Res 2001; 7: 2958-2970.
153. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031-1037.
154. Tran J, Master Z, Yu JL, Rak J, Dumont DJ, Kerbel RS. A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proc Natl Acad Sci USA 2002; 99: 4349-4354.
155. Kalyankrishna S, Grandis J. Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol 2006; 24: 2666-2672.
156. Bonner B, Harari P, Giralt J, et al. Radiotherapy plus cetuximab for squamous cell carcinoma of the head and neck. N Engl J Med 2006; 354: 567-578.
157. Heymach JV, Johnson BE, Prager D, et al. Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non-small cell lung cancer. J Clin Oncol 2007; 25: 4270-4277.
158. Bradshaw-Pierce EL, Steinhauer CA, Raben D, Gustafson DL. Pharmacokinetic-directed dosing of Vandetanib and Docetaxel in a mouse model of human squamous cell carcinoma. Mol Cancer Ther 2008; 7: 3006-3017.
159. Arakelyan, L., Selitser, V., Agur, Z.: US20040107084A1 (2004).
160. Jaffe CC. Response assessment in clinical trials: Implications for sarcoma clinical trial design. Oncologist 1008; 13: 14-18.
161. Sobol, R. E., Chada, S., Zumstein, L., Cvitkovic, E., Menander, K.: US20070231304 (2007).
162. 18FDG-PET scanning in oncology. Br J Cancer 2008; 98: 597-560.
163. Lalich M, McShane TM, Liu G. "Role of imaging in drug development" in "cancer imaging, Volume 2" First Edition by Hyatt, Elsevier Academic Press, Amsterdam 2008; 127-139.
164. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 205-216.
165. Schuetze SM, Baker LH, Benjamin RS, Canetta R. Selection of response criteria for clinical trials of sarcoma treatment. Oncologist 2008; 13: 32-40.
166. Smith, J.: US20030006770 (2003).
167. 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute trials. J Nucl Med 2006; 47: 1059-1066.
168. Weber W, Figlin R. Monitoring cancer treatment with PET/CT: Does it make a difference? J Nucl Med 2007; 48: 36-44.
169. Weber WA. Use of PET for monitoring cancer therapy and for predicting outcome. J Nucl Med 2005; 46: 983-995.
170. Kostakoglu L, Goldsmith SJ. PET in the assessment of therapy response in patients with sarcoma of the head and neck and of the esophagus. J Nucl Med 2004; 45: 56-68.
171. 18FDG PET/CT in the treatment of head and neck cancers: Posttherapy evaluation and pitfalls. Am J Roentgen 2005; 184: 589-597.
172. 18F-FDG PET evaluation of the response to therapy for lymphoma and for breast, lung, and colorectal carcinoma. J Nucl Med 2003; 44: 224-239.
173. Gregoire V, Haustermans K, Geets X, Roels S, Lonneux M. PET-based treatment planning in radiotherapy: A new standard? J Nucl Med 2007; 48; 68-77.
174. Kostakoglu L, Goldsmith SJ, Leonard JP, et al. FDG-PET after cycle 1 of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease. Cancer 2006; 107: 2678-2687.
175. Weber WA, Ott K, Becker K, et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 2001; 19: 3058-3065.
176. Ott K, Herrmann K, Lordick F, et al. Early metabolic response evaluation by fluorine-18 fluorodeoxyglucose positron emission tomography allows in vivo testing of chemosensitivity in gastric cancer: Long-term results of a prospective study. Clin Cancer Res 2008; 14: 2012-2018.
177. Hughes B, Yip D, Goldstein D, et al. Cerebral relapse of metastatic gastrointestinal stromal tumor during treatment with imatinib mesylate: Case report. BMC Cancer 2004; 4: 1-7.
178. 18F-Fluorodeoxyglucose positron emission tomography for monitoring response to sorafenib treatment in patients with hepatocellular carcinoma. Oncologist 2008; 13: 734-735.
179. Su H, Bodenstein C, Dumont RA, et al. Monitoring tumor glucose utilization by positron emission tomography for the prediction of treatment response to epidermal growth factor receptor kinase inhibitor. Clin Cancer Res 2006; 12: 5659-5667.
180. Galbraith SM. MR in oncology drug development. NMR Biomed 2006; 19: 681-689.
181. Pucar D, Shukla-Dave A, Hricak H, et al. Prostate cancer: correlation of MR imaging and MR spectroscopy with pathologic findings after radiation therapy - Initial experience. Radiology 2005; 236: 545-553.
182. Rosen MA, Schnall MD. Dynamic contrast-enhanced magnetic resonance imaging for assessing tumor vascularity and vascular effects of targeted therapies in renal cell carcinoma. Clin Cancer Res 2007; 13: 770s-776s.
183. Morgan B, Thomas AL, Drevs J, et al. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: Results from two Phase I studies. J Clin Oncol 2003; 21: 3955-3964.
184. Liu G, Rugo HS, Wilding G, et al. Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: Results from a phase I study. J Clin Oncol 2005; 23: 5464-5473.
185. Leach MO, Brindle KM, Evelhoch JL, et al. The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: Issues and recommendations. Br J Cancer 2005; 92: 1599-1610.
186. Gillies RJ, Raghunand N, Karczmar GS, Bhujwalla ZM. MRI of the tumor microenvironment. J Magn Reson Imag 2002; 16: 430-450.
187. Egeland TAM, Gaustas JV, Benjaminsen IC, et al. Assessment of fraction of hypoxic cells in human tumor xenografts with necrotic regions by dynamic contrast-enhanced MRI. Radiat Res 2008; 169: 289-299.
188. Raghunand N, Gatenby RA, Gillies RJ. Microenvironmental and cellular consequences of altered blood flow in tumors. Br J Radiol 2003; 76: 11-22.
189. Gaustad JV, Benjaminsen IC, Ruud EBM, et al. Dynamic contrast-enhanced magnetic resonance imaging of human melanoma xenografts with necrotic regions. J Magn Reson Imag 2007; 26: 133-143.
190. Frangioni JV. New technologies for human cancer imaging. J Clin Oncol 2008; 26: 4012-4021.
191. Radjenovic A, Dall BJ, Ridgway JP, Smith MA. Measurement of pharmacokinetic parameters in histologically graded invasive breast tumors using dynamic contrast-enhanced MRI. Br J Radiol 2008; 81: 120-128.
192. 11C-Vinblastine - syntheses and preliminary imaging in cancer patients. J Pharm Pharmaceut Sci 2007: 10: 266s-276s.
193. Saleem A, Aboagye EO, Matthews JC, Price PM. Plasma pharmacokinetic evaluation of cytotoxic agents radiolabelled with positron emitting radioisotopes. Cancer Chemother Pharmacol 2008; 61: 865-873.
194. 19F MRS pharmacokinetic studies of 5-fluorouracil. NMR Biomed 2007; 20: 128-140.
195. Holdsworth CH. Badawi RD, Manola JB, et al. CT and PET: Early prognostic indicators of response to imatinib mesylate in patients with gastrointestinal stromal tumors. Am J Roentgenol 2007; 189: W324-W330.
196. Zakian KL, Sircar K, Hricak, et al. Correlation of proton MR spectroscopic imaging with Gleason score based on step-selection pathologic analysis after radical prostatectomy. Radiology 2005; 234: 804-814.
197. Manton DJ, Chaturvedi A, Hubbard, et al. Neoadjuvant chemotherapy in breast cancer: Early response prediction with quantitative MR imaging and spectroscopy. Br J Cancer 2006; 94: 427-435.
198. Hamstra DA, Rahemtulla A, Ross BD. Diffusion magnetic resonance imaging: A biomarker for treatment response in oncology. J Clin Oncol 2007; 25: 4104-4109.
199. 18F-annexin as a PET imaging agent in an animal model of apoptosis. J Nucl Med 2005; 46: 658-666.
200. 18F]fluorothymidine positron emission tomography: The effect of cisplatin on a fibrosarcoma tumor model in vivo. Cancer Res 2005; 65: 2005.